Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Spotlight

GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines

Business

Deals
Earnings
Manufacturing

Policy & Regulation

Regulatory Landscape
Drug Pricing
IP & Litigation

Tools & Trackers

What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings

Conference Coverage

Partner Insights

Generics Bulletin Perspectives

Exploring market-shifting topics for the off-patent sector.

Generics Bulletin

Medtech Insight

Formycon Gets Date For Aflibercept Filing In US

US FDA Offers June 2024 Action Date For Coherus-Partnered FYB203 Eylea Biosimilar

Aug 29 2023

• By David Wallace

Eyes US flag — Formycon is eyeing a June 2024 FDA action date for FYB203 • Source: Shutterstock

Related Content

Viatris Believes Eylea Biosimilar Candidate Is First To Reach US FDA’s Desk

Nov 10 2021

Coherus Makes U-Turn On Eylea Biosimilar With Klinge BioPharma Deal

Jan 09 2023

Coherus’ Lucentis Biosimilar Outstrips Biogen Rival One Month After Launch

Nov 10 2022

Celltrion Is Latest To File Eylea Rival In US

Jun 30 2023

Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data

Feb 08 2023

Sandoz Puts Aflibercept In Its Sights With Phase III Data

Aug 16 2023

Triple Threat: EMA Endorses Three First-Time Biosimilars

Jul 21 2023

Related Companies

Formycon AG

Coherus Oncology, Inc.

Additional Topics

United States Biosimilars Strategy BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About

About UsOpens in new window
Meet the Team
AdvertiseOpens in new window
Contact Us

Account

My Account
My View
Email Preferences
Start Free TrialOpens in new window

More

Generics Top 50 Ranking
Biosimilars
Generics
Value Added Medicines

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window